References
- Maher D, Floyd K, Ravglione M. A strategic framework to decrease the burden of TB/HIV. Geneva: World Health Organization; 2002. Unpublished document WHO/CDS/TB 2002.296
- Nayyar A, Jain R. Recent advances in new structural classes of anti-tuberculosis agents. Curr Med Chem 2005;12:1873–86
- Lenaerts AJ, De Groote MA, Orme IM. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 2008;16:48–54
- Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359–74
- Phillips EJ, Uetrecht J, Walmsley SL. Drugs that affect cellular nucleic acid synthesis. In: Kalant H, Grant DM, Mitchell J, eds. Principles of medical pharmacology, 7th ed. Toronto: Saunders-Elsevier; 2007:715–16
- Pati HN, Das U, Sharma RK, Dimmock JR. Cytotoxic thiol alkylators. Mini Rev Med Chem 2007;7:131–9
- Mutus B, Wagner JD, Talpas CJ, et al. 1-p-Chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular weight thiols. Anal Biochem 1989;177:237–43
- Buluja G, Municio AM, Vega S. Reactivity of some α,β-unsaturated ketones with sulfhydryl compounds and their antifungal activity. Chem Ind 1964;2053–4
- Chhabria M, Jani M, Patel S. New frontiers in the therapy of tuberculosis: fighting with the global menace. Mini Rev Med Chem 2009;9:401–30
- Askling J, Ekbom A. Risk of non-Hodgkin’s lymphoma following tuberculosis. Br J Cancer 2001;84:113–15
- Kamboj M, Sepkowitz RA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006;42:1592–5
- Lin Y-M, Zhou Y, Flavin MT, et al. Chalcones and flavonoids as anti-tuberculosis agents. Bioorg Med Chem 2002;10:2795–802
- Perjesi P, Das U, De Clercq E, et al. Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells. Eur J Med Chem 2008;43:839–45
- Dimmock JR, Kandepu KM, Nazarali AJ, et al. Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones. J Med Chem 1999;42:1358–66
- Collins LA, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997;41:1004–9
- Valkonen A, Laihia K, Kolehmainen E, et al. Structural studies of seven homoisoflavonoids, six thiohomoisoflavonoids, and four structurally related compounds. Struct Chem 2012;23:209–17
- Hansch C, Leo AJ. Substituent constants for correlation analysis in chemistry and biology. New York: Wiley; 1979:49–50
- Taft RW Jr. Separation of polar, steric and resonance effects in reactivity. In: Newman MS, ed. Steric effects in organic chemistry. New York: Wiley Inc.; 1956:591
- Hansch C, Leo AJ. Substituent constants for correlation analysis in chemistry and biology. New York: Wiley; 1979:49
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:4–25
- Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714–7
- Veber DF, Johnson SR, Cheng H-Y, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23
- Kerns EH, Di L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. Boston: Academic Press; 2008:44–6
- Guillon J, Dumoulin H, Dallemagne P, et al. Synthesis and antituberculosis activity of new phenylpyrrolo[1,2a]quinoxalinylpyrrole carboxylic acid derivatives. Pharm Pharmacol Commun 1998;4:33–8
- Ancizu S, Moreno E, Solano B, et al. New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Bioorg Med Chem 2010;18:2713–19